As Ozempic, Wegovy Take Priority, Novo Nordisk Winds Down Insulin Portfolio In India
Advertisement
New Delhi: Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand. This decision is part of the company's global strategy to prioritize newer, patented therapies such as Ozempic and Wegovy.
Human Mixtard, despite being under price control, generates approximately Rs 800 crore annually for Novo Nordisk in India. The discontinuation will also affect other products in the Rs 5,000 crore insulin market like Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, primarily available in pre-filled disposable pens and cartridges (Penfill and FlexPen).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.